KEGG DRUG: Tisagenlecleucel-T

DRUG: Tisagenlecleucel-T

Entry

D11386                      Drug

Name

Tisagenlecleucel-T (USAN);
Tisagenlecleucel (INN);
Kymriah (TN)

Product

KYMRIAH (Novartis Pharmaceuticals Corporation)

Remark

ATC code:

L01XL04

Product:

D11386<US>

Efficacy

Antineoplastic, Anti-CD19 CAR-T cell

Disease

B-cell acute lymphoblastic leukemia [DS:H00001]

Type

Cellular therapy product, CAR-T cell therapy

Target

CD19 [HSA:930] [KO:K06465]

Pathway

hsa04640

Hematopoietic cell lineage

hsa04662

B cell receptor signaling pathway

Interaction

Brite

Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01X OTHER ANTINEOPLASTIC AGENTS
    L01XL Antineoplastic cell and gene therapy
     L01XL04 Tisagenlecleucel
      D11386  Tisagenlecleucel-T (USAN) <US>
Target-based classification of drugs [BR:br08310]
Cell surface molecules and ligands
  Other cell surface molecules
   CD molecules
    CD19
     D11386  Tisagenlecleucel-T (USAN) <US>
New drug approvals in the USA [br08319.html]
Cellular and gene therapy products
  D11386
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
  D11386
Cellular and gene therapy products
  D11386
New drug approvals in Japan [br08318.html]
Cellular and gene therapy products
  D11386
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
  D11386
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
  D11386

Other DBs

CAS:	1823078-37-0

PubChem:

384585364

» Japanese version » Back

All links

Ontology (7)   
   KEGG BRITE (7)   
Disease (2)   
   KEGG DISEASE (2)   
Chemical substance (1)   
   PubChem (1)   
Gene (2)   
   KEGG ORTHOLOGY (1)   
   KEGG GENES (1)   
All databases (12)   

Download RDF

DBGET integrated database retrieval system